Index Entries

Andrew Hill, Anna Garratt, Jacob Levi, Jonathan Falconer, Leah Ellis, Kaitlyn McCann, Victoria Pilkington, Ambar Qavi, Junzheng Wang, and Hannah Wentze
July 6, 2021
Open Forum Infectious Diseases

Retracted March 2022

Abstract: … This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality (Relative Risk 0.44 [95%CI 0.25-0.77]; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization.”

Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
https://academic.oup.com/ofid/article/9/3/ofac056/6523214 

On July 6, 2021, Open Forum Infectious Diseases published the article 'Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection' by Hill, et al. Subsequently, we and the authors learned that one of the largest studies on which this analysis was based was withdrawn due to fraudulent data; additional problems have emerged regarding other studies included in the original paper. An editorial Expression of Concern was first published under this record as the authors revised their analysis for resubmission.

The authors submitted and published a corrected version of the analysis with commentary on assessing trial quality while creating meta-analyses, available to read in OFID: 'Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud” by Hill et al., https://doi.org/10.1093/ofid/ofab645. The original analysis has been retracted.'"

document
COVID-19,ivermectin,medical treatments,pharmaceuticals